Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was a...
Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.
University of Pennsylvania, Department of Neurology, Philadelphia, Pennsylvania, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
Ohio State University, Columbus, Ohio, United States
Novartis Investigational site, Newcastle upon Tyne, United Kingdom
SIU School of Medicine, Springfield, Illinois, United States
St. Barnabas Medical Center, Livingston, New Jersey, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.